Immunologic aspects of vasculitis and cardiovascular disease

JAMA

Volumn 278, Issue 22, 1997, Pages 1962-1971

  Ledford, Dennis K ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

NEUTROPHIL CYTOPLASMIC ANTIBODY;

ALLERGIC VASCULITIS; AORTA ARCH SYNDROME; ATHEROSCLEROSIS; BACTERIAL ENDOCARDITIS; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CONNECTIVE TISSUE DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; GIANT CELL ARTERITIS; HEART DISEASE; HEART INFARCTION; HUMAN; IMMUNE RESPONSE; MORBIDITY; MORTALITY; MUCOCUTANEOUS LYMPH NODE SYNDROME; PRIORITY JOURNAL; PROGNOSIS; REPERFUSION INJURY; REVIEW; RHEUMATIC FEVER; VASCULITIS; VIRUS MYOCARDITIS; WEGENER GRANULOMATOSIS;

EID: 0031457119     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.278.22.1962     Document Type: Review

References (58)

1. Frank MF, Austen KF, Claman HC, Unanune ER, eds. Samter's Immunologic Disease. 5th ed. Boston, Mass: Little Brown & Co Inc; 1995.
2. Rich RR, Fleisher TA, Schwartz BD, Shearer WT, Strober W, eds. Clinical Immunology. St Louis, Mo: Mosby-Year Book Inc; 1996.
3. Paul WE, ed. Fundamental Immunology. 3rd ed. New York, NY: Raven Press; 1993.
4. Special Writing Group of the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young of the American Heart Association. Guidelines for the diagnosis of rheumatic fever: Jones criteria, 1992 update. JAMA. 1992;268:2069-2073.
5. Kassem AS, Zaher SR, Abou Shleib H, et al. Rheumatic fever prophylaxis using benzathine penicillin G (BPG): two-week versus four-week regimens: comparison of two brands of BPG. Pediatrics. 1996;97:992-995.
6. Dale JB, Chiang Ey, Lederer JW. Recombinant tetravalent group A streptococcal M protein vaccine. J Immunol. 1993;151:2188-2194.
7. Vasiljevic JD, Kanjuh V, Seferovic P. The incidence of myocarditis in endomyocardial biopsy samples from patients with congestive heart failure. Am Heart J. 1990;12:1370-1377.
8. Hypiä T. Etiological diagnosis of viral heart disease. Scand J Infect Dis. 1993;88(suppl):25-31.
9. Mason JW, O'Connell JB, Herskowitz A, et al. A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med. 1995;333:269-275.
10. Balaji S, Wiles HB, Sens MA, Gillette PL. Immunosuppressive treatment for myocarditis and borderline myocarditis in children with ventricular ectopic rhythm. Br Heart J. 1994;72:354-359.
11. Maione S, Valentin G, Giunta A, et al. Cardiac involvement in rheumatoid arthritis. Cardiology. 1993;83:234-241.
12. Lockshin MD, Bonfa E, Elkon K, Druzin ML. Neonatal lupus risk to newborns of mothers with systemic lupus erythematosus. Arthritis Rheum. 1988;31:697-701.
13. McAlister HF, Klementowica PT, Andrews C, et al. Lyme carditis: an important cause of reversible heart block. Ann Intern Med. 1989;110:339-345.
14. Treatment of Lyme disease. Med Lett Drugs Ther. 1997;39:47-48.
15. Libby P. Molecular basis of the acute coronary syndrome. Circulation. 1995;91:2844-2850.
16. Falk E, Shah PK, Fuster V. Pathogenesis of plaque disruption. In: Fuster V, Ross R, Topol EJ, eds. Atherosclerosis and Coronary Artery Disease. Philadelphia, Pa: Lippincott-Raven; 1996:492-511.
17. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation. 1994; 89:36-44.
18. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979.
19. Maseri A. Inflammation, atherosclerosis and ischemia events: exploring the hidden side of the moon. N Engl J Med. 1997;336:1014-1016.
20. Marx N, Neumann FJ, Ott I, et al. Induction of cytokine expression in leukocytes in acute myocardial infarction. J Am Coll Cardiol. 1997;30:165-170.
21. Neumann FJ, Marx N, Gurway M, et al. Induction of cytokine expression in leukocytes by binding of thrombin-stimulated platelets. Circulation. 1997; 95:2387-2394.
22. Neumann FJ, Ott I, Gurway M, et al. Cardiac release of cytokines and inflammatory response in acute myocardial infarction. Circulation. 1995;91: 748-755.
23. Kohler PF, Claman HV. Systemic vasculitis. In: Franklin EC, ed. Clinical Immunology Updates: A Review for Physicians. New York, NY: Elsevier Science Inc; 1981:293-319.
24. Bloch DA, Micel BA, Hunder GG, et al. The American College of Rheumatology 1990 criteria for the classification of vasculitis: patients and methods. Arthritis Rheum. 1990;33:1068-73.
25. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vaculitides: proposal of an international consensus conference. Arthritis Rheum. 1994;37:187-192.
26. Lie JT. Nomenclature and classification of vasculitis: plus ca change, plus c'est la meme chose. Arthritis Rheum. 1994;37:181-186.
27. Guillevin L, Lhote F, Cohen P, et al. Polyarteritis nodosa related to hepatitis B virus: a prospective study with long-term observation of 41 patients. Medicine. 1995;74:238-253.
28. Fries JF, Hunder GG, Bloch PA, et al. The American College of Rheumatology 1990 criteria for classification of vasculitis: summary. Arthritis Rheum. 1990;33:1065-1067.
29. Cohen-Tervaert JW, Limburg PC, Elema JD, et al. Detection of autoantibodies against myeloid lysosomal enzymes: a useful adjunct to classification of patients with biopsy-proven necrotizing arteritis. Am J Med. 1991;92:59-66.
30. Guillevin L, Visser H, Noel LH, et al. Antineutrophil cytoplasm antibodies in systemic polyarteritis nodosa with and without hepatiis B virus infection and Churg-Strauss syndrome - 62 patients. J Rheumatol. 1993;20:1345-1349.
31. Masi AT, Hunder GG, Lie JT, et al. The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum. 1990;33:1094-1100.
32. Lightfoot RW, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of polyarteritis. Arthritis Rheum. 1990;33:1088-1093.
33. Josefsen D. Asthma drug linked with Churg-Strauss syndrome. BMJ. 1997;315:330.
34. Guillevin L, Lhote F, Saubaget F, et al. Treatment of polyarteritis nodosa related to hepatitis B virus with interferon-alpha and plasma exchanges. Ann Rheum Dis. 1994;53:334-337.
35. Jordan SC. Treatment of systemic and renal-limited vasculitic disorders with pooled human intravenous immune globulin. J Clin Immunol. 1995; 15(suppl 6):76S-85S.
36. Schultz DR, Tozman EC. Antineutrophil cytoplasmic antibodies: major autoantigens, pathophysiology and disease associations. Semin Arthritis Rheum. 1995;25:143-159.
37. Specks U, Homburger HA. Anti-neutrophil cytoplasmic antibodies. Mayo Clin Proc. 1994;69:1197-1198.
38. Cotch MF, Hoffman GS, Yerg DE, Kaufman GI, Targonski P, Kaslow RA. The epidemiology of Wegener granulomatosis: estimates of the five-year period prevalence, annual mortality, and geographic disease distribution from population-based data sources. Arthritis Rheum. 1996;39:87-92.
39. Leavitt RY, Fauci AS, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Wegener granulomatosis. Arthritis Rheum. 1990;33:1101-1107.
40. Specks U, Homburger HA, DeRemee RA. Implications of c-ANCA testing for the classification of Wegener granulomatosis: performance of different detection systems. Adv Exp Med Biol. 1993;336:65-70.
41. Hoffman GS, Kerr GS, Leavitt RY, et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intent Med. 1992;116:48-98.
42. Hoffman GS, Leavitt RY, Kerr GS, et al. The treatment of Wegener granulomatosis with glucocorticoids and methotrexate. Arthritis Rheum. 1992;35:1322-1329.
43. Stegeman CA, Cohen Tervaert JW, deJong PE, Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener granulomatosis: Dutch co-trimoxazole Wegener study group. N Engl J Med. 1996;335:16-20.
44. Hunder GG, Block DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33:1122-8.
45. Rosefield SI, Komorsky GS, Klingele TG, et al. Treatment of temporal arteritis with ocular involvement. Am J Med. 1986;80:143-148.
46. Kerr G. Takyasu's areteritis. Curr Opin Rheumatol. 1994;6:32-38.
47. Kerr GS, Hallahan CW, Giordan J, et al. Takayasu arteritis. Ann Intern Med. 1994;120:919-921.
48. Joseph S, Mandalam KR, Rao VR, et al. Percutaneous transluminal angioplasty of the subclavian artery in nonspecific aortoarteritis: results of long-term follow-up. J Vasc Interv Radiol. 1994;5:573-580.
49. Puanamiya K, Bates ER, Shea MJ, Muller DW. Endoluminal stenting for unprotected left main stenosis in Takayasu's arteritis. Cathet Cardiovasc Diagn. 1997;40:276.
50. Calabrese LH, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of hypersensitivity vasculitis. Arthritis Rheum. 1990;33:1108-1113.
51. Melish ME, Hicks RV. Kawasaki syndrome: clinical features, pathophysiology, etiology, and therapy. J Rheumatol. 1990;17(suppl 24):2-10.
52. Leung DY. Immunologic aspects of Kawasaki syndrome. J Rheumatol. 1990;17(suppl 24):15-18.
53. Newburger JW, Takahasi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991;324: 1633-1639.
54. Salonen T, Yla-Herttuala S, Yamamoto R et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet. 1992;339:883-887.
55. Szekaneca Z, Shah MR, Pearce Wh, Koch AE. Human atherosclerotic abdominal aortic aneurysms produce interleukin (IL)-6 and interferon-gamma but not IL-2 and IL-4: the possible role for IL-6 and interferon-gamma in vascular inflammation. Agents Actions. 1994;42:159-162.
56. Frostegard J, Kjellman B, Gidlund M, Andersson B, Jindal S, Kiessling R. Induction of heat shock protien in monocytic cells by oxidized low density lipoprotein. Atherosclerosis. 1996;121:93-103.
57. Wick G, Schett G, Amberger A, Kleindienst R, Xu Q. Is atherosclerosis an immunologically mediated disease? Immunol Today. 1995;16:27-33.
58. George J, Harats D, Gilburd B, Shoenfeld Y. Emerging cross-regulatory roles of immunity and autoimmunity in atherosclerosis. Immunologic Res. 1996;15:315-332.